Alzheimer’s disease and cognitive decline
Prinnovation GmbH focuses on clinical research in Alzheimer’s disease, with attention to early symptomatic stages such as mild cognitive impairment and mild dementia. The sponsor’s research activity is centered on understanding therapeutic effects in patients with progressive memory and thinking impairment.
- Alzheimer’s disease
- mild cognitive impairment
- mild dementia
- cognitive impairment
The trial portfolio reflects an interest in treatments aimed at preserving daily function and slowing clinical worsening in neurodegenerative disease.
Neurology and neurodegenerative disorders
The sponsor’s clinical work is situated in neurology, with a specific therapeutic emphasis on disorders marked by progressive loss of cognition and memory. Research activity is directed toward treatment strategies relevant to neurodegeneration and the clinical management of symptomatic disease.
- neurology
- neurodegenerative disorders
- memory impairment
- symptomatic disease management
Clinical interest extends to disease states where cognitive testing and functional assessment are central to evaluating treatment impact.
Safety and tolerability
Prinnovation GmbH includes safety and tolerability as key areas of clinical interest in its research on therapies for Alzheimer’s disease. The sponsor’s studies examine how patients with early-stage disease respond to treatment in terms of adverse events and overall acceptability.
- safety
- tolerability
- adverse events
- treatment response
This focus supports clinical evaluation of medicines intended for long-term use in a vulnerable patient population.
Cognitive assessment and functional outcomes
The sponsor’s research activity includes clinical evaluation using measures that capture cognition and everyday function in patients with Alzheimer’s disease. Particular interest lies in outcomes that reflect disease burden and changes in clinical status over time.
- Clinical Dementia Rating-Sum of Boxes
- functional outcomes
- clinical assessment
- cognitive performance
These areas align with research in early dementia where both cognition and day-to-day function are important therapeutic targets.
